AZD5462

AZD5462 is an orally administered small molecule that acts as a selective allosteric agonist of the relaxin family peptide receptor 1 (RXFP1), which is the cognate receptor for human relaxin. By mimicking the actions of the pregnancy hormone relaxin H2 at RXFP1, AZD5462 activates downstream signaling pathways associated with anti-fibrotic and anti-inflammatory effects. The drug has demonstrated improvements in cardiac function in preclinical models and is being developed primarily for the treatment of chronic heart failure. Developed by AstraZeneca, AZD5462 has completed phase I studies in healthy volunteers and is currently undergoing phase II clinical trials to assess its efficacy and safety in patients with chronic heart failure[1][3][4][5][6][7][8].